Arcutis Biotherapeutics, Inc. ARQT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 90.9%+0.7pp | 90.2%+0.3pp | 90%+0.9pp | 89.1%+0.7pp | 88.4%-1.9pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.1× | 1×+0.2× | 0.8×+0.1× | 0.7×+0.1× | 0.5×-0.1× | |
| Inventory turnover | 1.4×-0.6× | 2×+0.2× | 1.8×-0.2× | 1.9×+0.2× | 1.7×+0.3× | |
| Liquidity | ||||||
| Current ratio | 2.7×-0.5× | 3.2×-0.3× | 3.5×+0.3× | 3.2×-0.4× | 3.6×-0.6× | |
| Quick ratio | 2.5×-0.5× | 3×-0.3× | 3.3×+0.2× | 3×-0.3× | 3.4×-0.6× | |
| Cash ratio | 0.2×-0.1× | 0.3×-0.1× | 0.5×-0.2× | 0.7×+0.1× | 0.6×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×0.0× | 0.6×-0.1× | 0.7×-0.1× | 0.8×0.0× | 0.8×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Per Share | ||||||
| Book value per share | $1.47-1.6% | $1.49+25.2% | $1.19+8.7% | $1.09-3.3% | $1.13-13.1% | |
| Valuation | ||||||
| Market capitalization | $2.92B-17.8% | $3.56B+57.4% | $2.26B+32.3% | $1.71B-7.9% | $1.86B+13.8% | |
| Enterprise value | $3B-17.3% | $3.63B+56.0% | $2.33B+33.3% | $1.75B-8.7% | $1.91B+14.6% | |
| Price / sales | 7×-2.4× | 9.5×+2.3× | 7.1×+0.6× | 6.5×-2.2× | 8.7×+0.4× | |
| Price / book | 15.4×-3.4× | 18.8×+4.5× | 14.3×+2.0× | 12.3×-0.7× | 13×+2.7× | |
| EV / sales | 7.2×-2.4× | 9.6×+2.3× | 7.3×+0.7× | 6.6×-2.4× | 9×+0.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Arcutis Biotherapeutics, Inc. (ARQT) runs a 90.9% gross margin and a -12.0% operating margin, with a -13.9% net margin.
- Where do Arcutis Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Arcutis Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.